GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
2,593.90
-73.05 (-2.74%)
At close: Feb 13, 2026
BOM:500660 Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Equivalents | - | 5,388 | 641.71 | 349.41 | 2,862 | 4,052 |
Short-Term Investments | - | 8,410 | 9,794 | 11,009 | 21,791 | 7,320 |
Trading Asset Securities | - | 11,182 | 8,132 | 5,183 | 3,656 | - |
Cash & Short-Term Investments | 20,609 | 24,981 | 18,568 | 16,541 | 28,309 | 11,372 |
Cash Growth | -2.36% | 34.54% | 12.25% | -41.57% | 148.94% | 7.10% |
Accounts Receivable | - | 2,925 | 2,221 | 1,924 | 2,052 | 2,156 |
Other Receivables | - | 682.8 | 1,275 | 1,373 | 715.31 | 254 |
Receivables | - | 3,608 | 3,496 | 3,297 | 2,768 | 2,410 |
Inventory | - | 4,817 | 5,250 | 4,600 | 5,347 | 5,467 |
Prepaid Expenses | - | 188.86 | 206.18 | 149.6 | 139.26 | 146.49 |
Other Current Assets | - | 503.25 | 463.33 | 355.04 | 517.62 | 2,631 |
Total Current Assets | - | 34,099 | 27,984 | 24,943 | 37,080 | 22,026 |
Property, Plant & Equipment | - | 2,839 | 3,107 | 3,151 | 3,254 | 3,554 |
Long-Term Investments | - | 0.27 | 0.27 | 0.27 | 0.15 | 0.15 |
Other Intangible Assets | - | 133.32 | 235.54 | 340.91 | 344.97 | 433.64 |
Long-Term Deferred Tax Assets | - | 1,409 | 1,463 | 1,335 | 1,131 | 1,031 |
Other Long-Term Assets | - | 2,601 | 2,776 | 2,795 | 2,621 | 4,101 |
Total Assets | - | 41,081 | 35,566 | 33,266 | 46,333 | 31,146 |
Accounts Payable | - | 7,082 | 6,254 | 4,278 | 5,793 | 4,661 |
Accrued Expenses | - | 2,215 | 1,655 | 1,482 | 4,622 | 2,066 |
Current Portion of Long-Term Debt | - | - | - | - | - | 0.24 |
Current Portion of Leases | - | 74.59 | 121.96 | 120.84 | 124.53 | 143.53 |
Current Income Taxes Payable | - | 5,245 | 2,986 | 2,962 | 2,962 | 1,637 |
Current Unearned Revenue | - | - | - | - | - | 1,800 |
Other Current Liabilities | - | 4,434 | 4,233 | 4,421 | 3,483 | 3,238 |
Total Current Liabilities | - | 19,052 | 15,249 | 13,264 | 16,984 | 13,546 |
Long-Term Leases | - | 24.92 | 64.69 | 34.55 | 76.24 | 202.5 |
Pension & Post-Retirement Benefits | - | 868.04 | 802.99 | 793.71 | 794.7 | 798.42 |
Other Long-Term Liabilities | - | 1,623 | 1,673 | 1,761 | 1,848 | 1,817 |
Total Liabilities | - | 21,568 | 17,790 | 15,853 | 19,703 | 16,364 |
Common Stock | - | 1,694 | 1,694 | 1,694 | 1,694 | 1,694 |
Retained Earnings | - | 18,371 | 16,549 | 15,920 | 25,210 | 13,345 |
Comprehensive Income & Other | - | -552.3 | -467.04 | -201.58 | -274.96 | -256.9 |
Shareholders' Equity | 17,077 | 19,513 | 17,776 | 17,413 | 26,630 | 14,783 |
Total Liabilities & Equity | - | 41,081 | 35,566 | 33,266 | 46,333 | 31,146 |
Total Debt | 357.1 | 99.51 | 186.65 | 155.39 | 200.77 | 346.27 |
Net Cash (Debt) | 20,252 | 24,882 | 18,382 | 16,386 | 28,108 | 11,026 |
Net Cash Growth | -3.38% | 35.36% | 12.18% | -41.70% | 154.93% | 8.10% |
Net Cash Per Share | 119.54 | 146.88 | 108.51 | 96.73 | 165.92 | 65.08 |
Filing Date Shares Outstanding | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 |
Total Common Shares Outstanding | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 |
Working Capital | - | 15,047 | 12,735 | 11,679 | 20,096 | 8,481 |
Book Value Per Share | 100.81 | 115.19 | 104.93 | 102.79 | 157.19 | 87.26 |
Tangible Book Value | 16,995 | 19,380 | 17,541 | 17,072 | 26,285 | 14,349 |
Tangible Book Value Per Share | 100.32 | 114.40 | 103.54 | 100.77 | 155.16 | 84.70 |
Land | - | 37 | 37 | 36.8 | 22.49 | 22.49 |
Buildings | - | 1,121 | 1,099 | 1,084 | 1,041 | 1,022 |
Machinery | - | 4,401 | 4,489 | 4,244 | 3,937 | 3,915 |
Construction In Progress | - | 143.2 | 139.3 | 203.12 | 305.02 | 132.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.